Evidence map›Paper›PMID 34119280›Full record

ReviewJournal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia2021

Intracerebral hemorrhage in COVID-19: A narrative review.

Nikolaos Panagiotis Margos, Andreas Stylianos Meintanopoulos, Dimitrios Filioglou, John Ellul

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Article
  6. COVID-19 and stroke in women: impact on clinical, psychosocial and research aspects.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Review
  7. Observational
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Neurological manifestation in COVID-19 disease with neuroimaging studies.American journal of neurodegenerative disease · 2023
    Review
  16. Article
  17. Article
  18. Ischemic and Hemorrhagic Cerebrovascular Events Related to COVID-19 Coagulopathy and Hypoxemia.International journal of environmental research and public health · 2022
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Nikolaos Panagiotis MargosSchool of Medicine, University of Patras, Institutional Address: University Campus, 26504 Rio, Greece. Electronic address: nikosmargos@yahoo.com.
Andreas Stylianos MeintanopoulosSchool of Medicine, University of Patras, Institutional Address: University Campus, 26504 Rio, Greece.
Dimitrios FilioglouSchool of Medicine, University of Patras, Institutional Address: University Campus, 26504 Rio, Greece.
John EllulDepartment of Neurology, University Hospital of Patras, Institutional address, 26500 Rio, Patras, Greece.
University of Patras · GRGeneral University Hospital of Patras · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus Disease 19 (COVID-19) pandemic affects the worldwide healthcare system and our understanding of this disease grows rapidly. Although COVID-19 is a mainly respiratory disease, neurological manifestations are not uncommon. The aim of this review is to report on the etiology, clinical profile, location, and outcome of patients with intracerebral hemorrhage (ICH) and COVID-19. This review includes 36 studies examining ICH in the clinical presentation of COVID-19. Overall, 217 cases with intracranial hemorrhage, of which 188 ICHs, were reported. Generally, a low incidence of both primary and secondary ICH was found in 8 studies [106 (0.25%) out of 43,137 hospitalized patients with COVID-19]. Available data showed a median age of 58 years (range: 52-68) and male sex 64%, regarding 36 and 102 patients respectively. Furthermore, 75% of the patients were on prior anticoagulation treatment, 52% had a history of arterial hypertension, and 61% were admitted in intensive care unit. Location of ICH in deep structures/basal ganglia was ascertained in only 7 cases making arterial hypertension an improbable etiopathogenetic mechanism. Mortality was calculated at 52.7%. Disease related pathophysiologic mechanisms support the hypothesis that SARS-CoV2 can cause ICH, however typical ICH risk factors such as anticoagulation treatment, or admission to ICU should also be considered as probable causes. Physicians should strongly suspect the possibility of ICH in individuals with severe COVID-19 admitted to ICU and treated with anticoagulants. It is not clear whether ICH is related directly to COVID-19 or reflects expected comorbidity and/or complications observed in severely ill patients.

Indexed as

AdultAgedAnticoagulantsBlood CoagulationCerebral HemorrhageCOVID-19COVID-19 Drug TreatmentHospitalizationHumansHypertensionIntensive Care UnitsMaleMiddle AgedPandemicsRisk FactorsSARS-CoV-2AnticoagulantsCOVID-19HemorrhageHemorrhagic strokeIntracerebralIntracranialIntraparenchymal

Identifiers

PMID34119280
PMCPMC8096173
OpenAlexW3159358365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.